PALOMA-3: Subcutaneous Amivantamab in Refractory EGFR-Mutated Advanced NSCLC

Taletrectinib emerges as a groundbreaking treatment for ROS1-mutant NSCLC, offering hope with its CNS activity and lower neurological side effects.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Taletrectinib gains FDA approval as a groundbreaking treatment for ROS1-positive non-small cell lung cancer, offering hope for patients with CNS involvement.

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

Oncologists share their treatment preferences for patients with advanced NSCLC with EGFR mutations.

A recent study reveals promising outcomes for lung cancer patients who undergo rechallenge with different RET inhibitors after initial treatment failure.